ThioTEPA

180px
ThioTEPA
Systematic (IUPAC) name
N,N ' N '-triethylenethiophosphoramide
Identifiers
CAS number	52-24-4
ATC code	L01AC01
PubChem	5453
Chemical data
Formula	C6H12N3PS
Mol. mass	189.219 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic (CYP2B6, CYP2C11)
Half life	2.4 hours 15-18 hours (metabolites)
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	D(AU) D(US)
Legal status	POM(UK) ℞-only(US)
Routes	IV, intracavitary, intravesical

WikiDoc Resources for ThioTEPA
Articles
Most recent articles on ThioTEPA Most cited articles on ThioTEPA Review articles on ThioTEPA Articles on ThioTEPA in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ThioTEPA Images of ThioTEPA Photos of ThioTEPA Podcasts & MP3s on ThioTEPA Videos on ThioTEPA
Evidence Based Medicine
Cochrane Collaboration on ThioTEPA Bandolier on ThioTEPA TRIP on ThioTEPA
Clinical Trials
Ongoing Trials on ThioTEPA at Clinical Trials.gov Trial results on ThioTEPA Clinical Trials on ThioTEPA at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ThioTEPA NICE Guidance on ThioTEPA NHS PRODIGY Guidance FDA on ThioTEPA CDC on ThioTEPA
Books
Books on ThioTEPA
News
ThioTEPA in the news Be alerted to news on ThioTEPA News trends on ThioTEPA
Commentary
Blogs on ThioTEPA
Definitions
Definitions of ThioTEPA
Patient Resources / Community
Patient resources on ThioTEPA Discussion groups on ThioTEPA Patient Handouts on ThioTEPA Directions to Hospitals Treating ThioTEPA Risk calculators and risk factors for ThioTEPA
Healthcare Provider Resources
Symptoms of ThioTEPA Causes & Risk Factors for ThioTEPA Diagnostic studies for ThioTEPA Treatment of ThioTEPA
Continuing Medical Education (CME)
CME Programs on ThioTEPA
International
ThioTEPA en Espanol ThioTEPA en Francais
Business
ThioTEPA in the Marketplace Patents on ThioTEPA
Experimental / Informatics
List of terms related to ThioTEPA

Overview

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

References

• Sykes M et al. (1953). "Clinical Studies of triethylenephosphoramide compounds with nitrogen mustard-like activity". Cancer 6: 142-48.
• Maanen MJ, Smeets CJ, Beijnen JH (2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treat Rev 26 (4): 257-68. PMID 10913381.